Showing results (211-220 of 4,494) with videos related to

Sort By:
Pageof 450
Advances in Therapy|April 20, 2020
Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U300 in the Netherlands: Evidence From a Randomised Controlled TrialMarc Evans, Robert G J Moes, Katrine S Pedersen, et al.
Advances in Therapy|April 25, 2020
Developing Classifications of Laryngeal Dysplasia: The Historical BasisHenrik Hellquist, Alfio Ferlito, Antti A Mäkitie, et al.
Advances in Therapy|June 15, 2020
Correction to: Real-World Treatment Patterns, Adverse Events, Resource Use, and Costs Among Commercially Insured, Younger Patients with Chronic Lymphocytic Leukemia in the USA: A Retrospective Cohort StudyShaum M Kabadi, Aimee Near, Keiko Wada, et al.
Advances in Therapy|August 18, 2016
Systematic Review of Current Devices for 24-h Intraocular Pressure MonitoringSabita M Ittoop, Jeffrey R SooHoo, Leonard K Seibold, et al.
Advances in Therapy|August 29, 2025
Effectiveness of Mepolizumab in Patients with OCS-Dependent Severe Asthma: A Real-World StudySevim Bavbek, Mona Al-Ahmad, Hala Samaha, et al.
Advances in Therapy|September 3, 2025
Pharmacokinetic Bridging Between an Autoinjector and a Prefilled Syringe Following Subcutaneous Administration of Mirikizumab in Healthy ParticipantsXin Zhang, Yuki Otani, Christopher D Payne, et al.
Advances in Therapy|May 21, 2021
The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on 'Off'-time in Patients with Advanced Parkinson's Disease: A Systematic ReviewAngelo Antonini, Per Odin, Rajesh Pahwa, et al.
Advances in Therapy|May 12, 2021
Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor AgonistsJamy Ard, Angela Fitch, Sharon Fruh, et al.
Advances in Therapy|May 12, 2021
One in Seven Insulin-Treated Patients in Developing Countries Reported Poor Persistence with Insulin Therapy: Real World Evidence from the Cross-Sectional International Diabetes Management Practices Study (IDMPS)Juliana C N Chan, Juan José Gagliardino, Hasan Ilkova, et al.
Advances in Therapy|May 20, 2021
Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label StudyJai Perumal, Roumen Balabanov, Ray Su, et al.
Pageof 450